-
High-yield, early maturity, strong disease resistance scientists bred 38 new lily varieties
Time of Update: 2021-10-11
High-yield, early maturity, strong disease resistance scientists bred 38 new lily varietiesScience and Technology Daily News (Reporter Yu Huiyou) cultivated 38 new varieties and varieties of ornamental and edible lilies, developed 1 new product of lily sauce wine, reserved 11 invention patents, and promoted and applied more than 90,000 mu in 8 years .
-
Amgen vs. Mirati KRAS inhibitors siege colorectal cancer
Time of Update: 2021-10-11
Currently, Mirati is carrying out Phase 3 clinical trials to evaluate the efficacy and safety of combination therapy in the second-line treatment of KRASG12C mutant CRC patients (NCT04793958) .
-
Chuangsheng Group announced that its anti-sclerostin monoclonal antibody TST002 was approved for clinical use in China
Time of Update: 2021-10-11
Suzhou, September 27, 2021/PRNewswire/ - Chuangsheng Group, a clinical-stage biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical discovery, R&D, process development and production, announced today that it is targeting severe osteoporosis The anti-sclerostin monoclonal antibody TST002 was officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on September 22.
-
Investigation shows: Strengthening awareness of the epidemic may help curb infectious diseases and wildlife protection
Time of Update: 2021-10-11
The survey found that in some parts of Asia, people who have a higher self-reported awareness of the new crown pneumonia (COVID-19) epidemic may reduce the consumption of wild animal products by up to 24% in the future .
-
Over 1.7 billion U.S. dollars to help develop ophthalmic gene therapy AbbVie reached cooperation
Time of Update: 2021-10-11
On September 13, 2021, AbbVie and REGENXBIO announced a strategic cooperation agreement to jointly develop and commercialize RGX-314 .
RGX-314 is a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and other chronic retinal diseases .
-
ThinkSono DVT testing software results announced
Time of Update: 2021-10-11
Researchers from the University of Oxford, Imperial College and University of Sheffield collaborated with technology company ThinkSono (led by Fouad Al-Noor and Sven Mischkewitz) to train machine learning AI algorithms (AutoDVT) to distinguish DVT patients from non-DVT patients .
-
Assist stroke patients to restore motor function U.S. FDA approves nerve stimulation therapy
Time of Update: 2021-10-11
This is a non-drug-based rehabilitation system designed to use electrical vagus nerve stimulation (VNS) to treat moderate/severe upper extremity motor deficits associated with chronic ischemic stroke .
-
Studies have found that the COVID-19 pandemic has caused the greatest drop in life expectancy since World War II
Time of Update: 2021-10-11
Ridy Kashyap, co-lead author of the study, said: "The dramatic decline in life expectancy in the United States is partly due to the significant increase in the mortality rate of the working-age population in 2020.
-
Immune stimulant coupled with monoclonal antibody Cinda Biosciences collaborates to develop innovative anti-cancer therapies
Time of Update: 2021-10-11
The two parties will combine Cinda's proprietary antibody drug portfolio and R&D capabilities for undisclosed tumor targets, and Bolt's advanced ISAC technology and expertise in the field of myeloid cells to jointly develop three new anti-cancer immunotherapy drugs, which are expected to provide patients Bring significant benefits .
-
Dual-target anti-cancer RNAi therapy!
Time of Update: 2021-10-11
The synergistic effect of dual-targeted PD-1 and BRD4 shows excellent anti-tumor efficacy and cure rate (Source: Phio)In addition to a higher rate of complete remission, mPH-3861 treatment also induced a long-lasting systemic anti-tumor immune response .
-
Researchers Announce Important Research on Doxagliptin Diabetes Remission
Time of Update: 2021-10-11
Shanghai, September 26, 2021/PRNewswire/ - Hua Medicine (the "Company", Hong Kong Stock Exchange stock code: 2552. HK) today announced the 6th China Pharmaceutical Innovation and Investment Conference
-
Cell: MIT research discovers new targets for future cancer vaccines
Time of Update: 2021-10-11
Researchers at the Massachusetts Institute of Technology (MIT) found that vaccines against certain cancer proteins can increase the overall T cell response in mice and help shrink tumors .
-
Focus on patients with immune thrombocytopenia Fosun Health and various parties launch Health Care Month
Time of Update: 2021-10-11
The Care Month project from September 1 to September 30 calls on the public to pay attention to early disease prevention, and carry out free consultations, expert live broadcasts, popular science education and other activities through a combination of online and offline methods to care for patients with blood diseases and tumors, and help patients light up Starlight, regain confidence .
-
Two styles a day! Purmis Biologics Bispecific Antibody New Drug Approved for Clinical Clinic
Time of Update: 2021-10-11
PM8001: Advanced lung cancerPM8001: Advanced lung cancerPublic information shows that PM8001 is the first bispecific antibody in many anti-tumor projects of Pumis Biosciences, and it is also the first new drug project that the company has fully promoted .
-
Boehringer Ingelheim's new technology for immunotherapy against cancer cell antigens
Time of Update: 2021-10-11
Abexxa focuses on the development of innovative immunotherapies around the intracellular antigens presented by atypical major histocompatibility complex (MHC) class I molecules on cancer cells to directly kill tumors or mediate tumor death through immune regulation .
-
The new coronavirus vaccine is effective against the mutant strain in animal trials
Time of Update: 2021-10-11
By displaying the protein of the new coronavirus on the surface of this virus-like particle, researchers have developed this new vaccine, which can be recognized by the immune system of mammals but is not infectious .
-
The first oral therapy!
Time of Update: 2021-10-11
On September 15, Takeda announced that the FDA has accelerated the approval of Exkivity (mobocertinib) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adults who carry EGFR exon 20 insertion mutations and undergo disease progression after platinum-based chemotherapy.
-
Accelerated heartbeat may affect the brain to make judgments?
Time of Update: 2021-10-11
The time it takes to make a decision is related to the heart rate (picture source: reference [1])While the monkeys are making decisions, the researchers also analyzed their brain activity.
-
Newly identified a potential cause of severe COVID-19
Time of Update: 2021-10-11
"Professor Jindrich Cinatl of the Goethe University in Frankfurt said: "These additional insights into the disease process behind COVID-19 may help us design better therapies and recognize the importance of the breadth of ongoing research .
-
Scynexis antifungal drug launched in the U.S. to treat vulvovaginal candidiasis only requires one day of medication
Time of Update: 2021-10-11
The results from two phase 3 clinical studies of the VANISH project show that Brexafemme is effective, safe and well tolerated in the treatment of VVC for one day .
